DOCSLIB.ORG

Upadacitinib for Psoriatic Arthritis Refractory to Biologics: SELECT-Psa 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Upadacitinib for Psoriatic Arthritis Refractory to Biologics: SELECT-Psa 2 Ann Rheum Dis: first published as 10.1136/annrheumdis-2020-218870 on 3 December 2020. Downloaded from Psoriatic arthritis CLINICAL SCIENCE Upadacitinib for psoriatic arthritis refractory to biologics: SELECT- PsA 2 Philip J Mease ,1,2 Apinya Lertratanakul,3 Jaclyn K Anderson ,3 Kim Papp,4 Filip Van den Bosch,5 Shigeyoshi Tsuji,6 Eva Dokoupilova,7,8 Mauro Keiserman,9 Xin Wang,3 Sheng Zhong,3 Reva M McCaskill,3 Patrick Zueger,3 Aileen L Pangan,3 William Tillett10,11 Handling editor Josef S ABSTRACT Key messages Smolen Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis ► Additional material is What is already known about this subject? published online only. To view (PsA). We evaluated upadacitinib in patients with PsA ► Despite the availability of biologic disease- please visit the journal online and prior inadequate response or intolerance to at least modifying antirheumatic drugs (DMARDs) in (http:// dx. doi. org/ 10. 1136/ one biologic disease- modifying antirheumatic drug psoriatic arthritis, only a small proportion of annrheumdis- 2020- 218870). (DMARD). patients achieve the recommended target of Methods In this 24-week randomised, placebo- For numbered affiliations see minimal disease activity; therefore, additional controlled, double-blind, phase 3 trial, 642 patients were end of article. treatment options are needed. randomised (2:2:1:1) to once per day upadacitinib 15 Correspondence to mg or 30 mg, placebo followed by upadacitinib 15 mg What does this study add? Dr Philip J Mease, or placebo followed by upadacitinib 30 mg at week 24. In this phase 3 trial of patients with psoriatic Rheumatology, Swedish Medical The primary endpoint was the proportion of patients ► Center, Seattle WA 98122, USA; arthritis refractory or intolerant to biologic achieving American College of Rheumatology (ACR) 20 pmease@ philipmease. com DMARDs, greater efficacy was demonstrated response at week 12. Achievement of minimal disease for once per day upadacitinib 15 mg and 30 Received 13 August 2020 activity (MDA) was assessed at week 24. Treatment- mg versus placebo for clinical manifestations Revised 22 September 2020 emergent adverse events are reported for all patients Accepted 12 October 2020 of psoriatic arthritis including musculoskeletal who received at least one dose of trial drug. symptoms (peripheral arthritis, enthesitis, Results At week 12, significantly more patients dactylitis and spondylitis), psoriasis, physical receiving upadacitinib 15 mg and 30 mg versus placebo function, pain, fatigue and quality of life. achieved ACR20 (56.9% and 63.8% vs 24.1%; p<0.001 for both comparisons). At week 24, MDA was achieved How might this impact on clinical practice or by more upadacitinib 15 mg-treated (25.1%) and 30 future developments? mg- treated patients (28.9%) versus placebo (2.8%; Once per day upadacitinib 15 mg and 30 mg p<0.001 for both comparisons). Generally, the rates ► demonstrated significant efficacy in patients http://ard.bmj.com/ of treatment-emergent adverse events were similar with psoriatic arthritis refractory or intolerant to with placebo and upadacitinib 15 mg and higher prior biologic DMARD therapy in the 24-week with upadacitinib 30 mg at week 24. Rates of serious placebo- controlled period of this study. infections were 0.5%, 0.5% and 2.8% with placebo, Efficacy was observed as early as week 2. upadacitinib 15 mg and upadacitinib 30 mg, respectively. ► Efficacy was demonstrated in all measures of Conclusion In this trial of patients with active PsA who the various core clinical domains of psoriatic had inadequate response or intolerance to at least one on September 30, 2021 by guest. Protected copyright. arthritis. More upadacitinib-treated patients biologic DMARD, upadacitinib 15 mg and 30 mg was achieved a state of minimal disease activity. more effective than placebo over 24 weeks in improving The safety findings are consistent with the signs and symptoms of PsA. ► known safety profile of upadacitinib observed Clinical trial registration number NCT03104374 in rheumatoid arthritis; no new safety risks have been identified. © Author(s) (or their INTRODUCTION employer(s)) 2020. Re- use Psoriatic arthritis (PsA) is a systemic inflammatory by other approved therapies.1–3 While multiple permitted under CC BY- NC. No disease with heterogeneous clinical manifesta- therapeutic choices are now available, additional commercial re- use. See rights tions such as plaque psoriasis, arthritis, dactylitis options are needed as under one- third achieving and permissions. Published by BMJ. and enthesitis. Current treatment guidelines for minimal disease activity (MDA) in most placebo- PsA vary, recommending conventional synthetic controlled trials.4–9 To cite: Mease PJ, disease- modifying antirheumatic drugs (DMARDs) Upadacitinib is an oral, reversible Janus kinase Lertratanakul A, such as methotrexate as initial therapy, followed by inhibitor (JAKi) with selectivity for JAK1 over Anderson JK, et al. 10 Ann Rheum Dis Epub ahead biologic DMARDs (tumour necrosis factor inhibi- JAK2, JAK3 and tyrosine kinase 2, approved for of print: [please include Day tors (TNFi), interleukin-12/23 or interleukin-17 the treatment of rheumatoid arthritis based on five Month Year]. doi:10.1136/ inhibitors) or targeted synthetic DMARDs, such as phase 3 studies.11–15 Improvements in multiple annrheumdis-2020-218870 apremilast or tofacitinib, or TNFi initially, followed composite measures, including stringent measures Mease PJ, et al. Ann Rheum Dis 2020;0:1–9. doi:10.1136/annrheumdis-2020-218870 1 Ann Rheum Dis: first published as 10.1136/annrheumdis-2020-218870 on 3 December 2020. Downloaded from Psoriatic arthritis of low disease activity and remission, as well as patient-reported 12. Multiplicity-controlled secondary endpoints for each dose outcomes such as morning stiffness and pain, after treatment of upadacitinib versus placebo included: at week 12, change with upadacitinib 15 mg once per day, in patients with rheuma- from baseline in Health Assessment Questionnaire-Disability toid arthritis who failed biologic DMARDs were similar to those Index (HAQ- DI)17; Functional Assessment of Chronic Illness in patients who had failed conventional synthetic DMARDs or Therapy- Fatigue (FACIT- F) score18 and Short Form Health methotrexate.11–15 We report the results of the SELECT- PsA 2 Survey questionnaire (SF-36) Physical Component Summary trial, a randomised phase 3 trial of upadacitinib in patients with (PCS) score19; at week 16, proportion of patients achieving a active PsA who have had an inadequate response or intolerance Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or to at least one biologic DMARD. 1 and at least a 2 point improvement from baseline (sIGA 0/1) for patients with baseline sIGA ≥220; Psoriasis Area Severity PATIENTS AND METHODS Index (PASI)75 response for patients with ≥3% BSA- psoriasis at baseline21; and change from baseline in Self- Assessment Patients 22 Eligible patients were 18 years of age or older with active PsA, had of Psoriasis Symptoms (SAPS) Questionnaire ; and at week 23 a diagnosis of PsA with symptom onset for ≥6 months, fulfilled 24, proportion of patients achieving MDA. Additional key the Classification Criteria for Psoriatic Arthritis (CASPAR),16 secondary efficacy endpoints included ACR50/70 response had historical or current plaque psoriasis, ≥3 swollen joints (of at week 12 and ACR20 response at week 2. Exploratory 66) and ≥3 tender joints (of 68) at screening and at baseline, and endpoints were proportion of patients achieving PASI90/100 an inadequate response or intolerance to at least one biologic response, resolution of enthesitis (defined by Leeds Enthesitis 24 DMARD. Patients were excluded if they had previous exposure Index (LEI)=0) for patients with baseline LEI >0 and Spon- to a JAKi, had a history of fibromyalgia, had arthritis with onset dyloarthritis Research Consortium of Canada Enthesitis Index prior to age 17 years or had diagnosis of inflammatory joint ((SPARCC)=0) for patients with baseline SPARCC Enthesitis 25 disease other than PsA. Online supplemental section 2 provides Index>0 and resolution of dactylitis (defined by Leeds 26 a complete list of eligibility criteria. Dactylitis Index (LDI)=0) for patients with baseline LDI>0, and change from baseline in individual components of ACR response, Disease Activity in Psoriatic Arthritis (DAPSA) Trial design score,27 and morning stiffness (mean of Bath Ankylosing Spon- A multicentre, randomised, double- blind, phase 3 placebo- dylitis Disease Activity Index (BASDAI) questions 5 and 6). All controlled trial at 123 sites in 17 countries has been ongoing outcomes are defined in online supplemental table S1. since April 2017, conducted per the International Conference on Adverse events (AEs) and clinical laboratory testing are Harmonization guidelines, applicable regulations and guidelines reported through week 24. An independent, external Cardio- governing clinical trial conduct, and the Declaration of Helsinki. vascular Adjudication Committee blindly adjudicated deaths All patients provided written informed consent. and cardiovascular events per predefined event definitions. An internal Gastrointestinal (GI) Perforation Adjudication Randomisation and treatments Committee blindly adjudicated reported GI perforation An Interactive Response Technology system was used to assign events as stated in the GI perforation charter. patients, in a 2:2:1:1 ratio, to one of the following
Load more

Recommended publications
  • Pharmacy Prior Authorization Criteria
    Central California Alliance for Health Pharmacy Prior Authorization Criteria March 2020 Notice of Nondiscrimination and Accessibility Discrimination is Against the Law Central California Alliance for Health (the Alliance) complies with Federal civil rights and nondiscrimination laws to make sure all members have access to its programs and services. This means that the Alliance does not exclude or treat members differently because of race, color, national origin, age, disability, or sex. The Alliance provides services, at no cost, to help members communicate with us. • Members with a disability can ask for: ○ A trained sign language interpreter, and ○ Written information in large print, audio, easy to use electronic formats and other formats. • Members whose primary language is not English can ask for: ○ A trained language interpreter, and ○ Information written in a language they can understand. If you need these services, contact the Alliance Member Services Department at 1-800-700-3874 or if you believe that the Alliance did not provide these services or treated you differently because of race, color, national origin, age, disability, or sex, you can file a grievance in any of these ways: Phone: 1-800-700-3874 ext. 5816 Website: https://www.ccah-alliance.org/Complaints.html Fax: 1-831-430-5579 Email: [email protected] Mail: Grievance Department 1600 Green Hills Road, Suite 101 Scotts Valley, CA 95066 If you need help filing a grievance, our Member Service Representatives and Grievance Coordinators can help you. Contact the Alliance Member Services Department at 1-800-700-3874 or Grievance Department at 1-800-700-3874, ext.
    [Show full text]
  • WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT (51) International Patent Classification: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 A 61K 35/1 7 (20 15.0 1) A 61P 35/00 (2006 .0 1) Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US). (21) International Application Number: (72) Inventor: ALBERTSON, Tina; 400 Dexter Ave. N., Suite PCT/US2018/035755 1200, Seattle, WA 98109 (US). (22) International Filing Date: (74) Agent: AHN, Sejin et al; Morrison & Foerster LLP, 1253 1 0 1 June 2018 (01 .06.2018) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 14,774 02 June 2017 (02.06.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/5 15,530 05 June 2017 (05.06.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/521,366 16 June 2017 (16.06.2017) u s HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/527,000 29 June 2017 (29.06.2017) u s KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/549,938 24 August 2017 (24.08.2017) u s MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/580,425 0 1 November 2017 (01 .11.2017) u s OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/593,871 0 1 December 2017 (01 .12.2017) u s SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/596,764 08 December 2017 (08.12.2017) u s TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Accepted Manuscript
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2020 JAK efficacy in Crohn’s disease Rogler, Gerhard Abstract: Inhibition of Janus kinases in Crohn’s disease (CD) patients has shown conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor showed efficacy in ulcerative colitis (UC) and has been approved for the treatment of patients with moderate to severe UC. In contrast, studies in patients suffering from CD were disappointing and the primary endpoint of clinical remission could notbemet in the respective phase II induction and maintenance trials. Subsequently, the clinical development of tofacitinib was discontinued in CD. In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, inCD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. Subse- quently phase III programs in CD have been initiated for both substances, which are still ongoing. Several newer molecules of this class of orally administrated immunosuppressants are tested in clinical programs. The concern of side effects of systemic JAK inhibition is addressed by either exclusively intestinal action or higher selectivity (Tyk2 inhibitors). In general, JAK inhibitors constitute a new promising class of drugs for the treatment of CD. DOI: https://doi.org/10.1093/ecco-jcc/jjz186 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-178518 Journal Article Accepted Version Originally published at: Rogler, Gerhard (2020). JAK efficacy in Crohn’s disease.
    [Show full text]
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Summary Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211675Orig1s000 SUMMARY REVIEW Cross Discipline Team Leader Review NDA 211675 Division Director Sununa1y Rinvoq (upadacitinib) for RA Office Director Sununary AbbVie , Inc. DHHS/FDA/CDER/ODEII/DPARP Cross-Discipline Team Leader Review Division Director Summary Office Director Summary Date July 11 , 201 9 Rachel Glaser, MD, Clinical Team Leader, DPARP From Sally Seymour, MD, Director, DP ARP Marv Thanh Hai, MD, Acting Director, ODEII Cross-Discipline Team Leader Review Subject Division Director Summaiy Office Director Summary NDA/BLA # and Supplement# 211675 Applicant AbbVie fuc Date of Submission December 18, 201 8 PDUFA Goal Date AUITTlSt 18, 201 9 Proprietary Name RINVOO Established or Proper Name Uoadacitinib Dosa2e Form(s) 15 mg extended release tablets Applicant Proposed (b)(4 Indication(s )/Population(s) Applicant Proposed Dosing 15 mg orally administered once daily Reoimen(s) Recommendation on Regulatory Approval Action Recommended Treatment of adults with moderately to severely active lndication(s)/Population(s) (if rheumatoid ai1hritis who have had an inadequate aoolicable) resoonse or intolerance to methotrexate Recommended Dosing 15 mg orally administered once daily Re2imen(s) (if aoolicable) CDER Cross Discipline Team Leader Review Template 1 Version date: October 10, 2017fo r all NDAs and BLAs Reference ID: 4478224 Cross Discipline Team Leader Review NDA 211675 Division Director Summary Rinvoq (upadacitinib) for RA Office Director Summary AbbVie, Inc. DHHS/FDA/CDER/ODEII/DPARP 1. Benefit-Risk Assessment Benefit-Risk Assessment Framework Rheumatoid arthritis (RA) is a serious medical condition that affects over 1.3 million Americans. RA is a chronic progressive disease that primarily affects the joints, but can involve other organs.
    [Show full text]
  • Switching Between Janus Kinase Inhibitor Upadacitinib and Adalimumab Following Insufficient Response: Efficacy and Safety In
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2020-218412 on 4 November 2020. Downloaded from Rheumatoid arthritis CLINICAL SCIENCE Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis Roy M Fleischmann ,1 Ricardo Blanco ,2 Stephen Hall,3 Glen T D Thomson,4 Filip E Van den Bosch,5,6 Cristiano Zerbini,7 Louis Bessette,8,9 Jeffrey Enejosa,10 Yihan Li,10 Yanna Song,10 Ryan DeMasi,10 In- Ho Song10 Handling editor Josef S ABSTRACT Key messages Smolen Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or ► Additional material is What is already known about this subject? published online only. To view, vice versa, in patients with rheumatoid arthritis with non- ► In patients with rheumatoid arthritis, a treat- please visit the journal online response or incomplete- response to the initial therapy. to- target strategy is recommended, in which (http:// dx. doi. org/ 10. 1136/ Methods SELECT-COMP ARE randomised patients to therapy is optimised every 3–6 months until annrheumdis- 2020- 218412). upadacitinib 15 mg once daily (n=651), placebo (n=651) remission, or low disease activity, is achieved. or adalimumab 40 mg every other week (n=327). A For numbered affiliations see Recent treatment recommendations suggest the treat-to- target study design was implemented, with end of article. addition of a biological or targeted- synthetic blinded rescue occurring prior to week 26 for patients disease- modifying antirheumatic drug in Correspondence to who did not achieve at least 20% improvement in both patients who do not achieve treatment goals, Dr Roy M Fleischmann, The tender and swollen joint counts (’non-responders’) and and switches between mechanisms of action University of Texas at week 26 based on Clinical Disease Activity Index Southwestern Medical Center, occur commonly in clinical practice.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use Extended-release tablets: 15 mg (3) RINVOQ safely and effectively. See full prescribing information for RINVOQ. CONTRAINDICATIONS • None (4) RINVOQ™ (upadacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2019 WARNINGS AND PRECAUTIONS • Serious Infections: Avoid use of RINVOQ in patients with active, serious WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND infection, including localized infections. (5.1) THROMBOSIS • Malignancy: Consider the risks and benefits of RINVOQ treatment prior to initiating therapy in patients with a known malignancy. (5.2) See full prescribing information for complete boxed warning. • Thrombosis: Consider the risks and benefits prior to treating patients who • Serious infections leading to hospitalization or death, including may be at increased risk of thrombosis. Promptly evaluate patients with tuberculosis and bacterial, invasive fungal, viral, and other symptoms of thrombosis and treat appropriately. (5.3) opportunistic infections, have occurred in patients receiving RINVOQ. • Gastrointestinal Perforations: Use with caution in patients who may be at (5.1) increased risk. (5.4) • If a serious infection develops, interrupt RINVOQ until the infection is • Laboratory Monitoring: Recommended due to potential changes in controlled. (5.1) lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids. (5.5) • Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is • Embryo-Fetal Toxicity: RINVOQ may cause fetal harm based on animal positive, start treatment for tuberculosis prior to starting RINVOQ. studies. Advise females of reproductive potential of the potential risk to a (5.1) fetus and to use effective contraception.
    [Show full text]
  • Journal of Managed Care & Specialty Pharmacy®
    J MC P ■ Journal of Mana of Journal JOURNAL OF g ANAGED ed Care & Specialty Pharmac M CARE & SPECIALTY PHARMACY® y ■ October 2020 Supplement ■ Volume 26 ■ Number 10-a ■ October 2020 ■ Supplemen t ■ Vol. 26, No. 10-a Making the Way for Innovation 2020 VIRTUAL • WEEK OF OCT. 19 Poster Abstracts Journal of Managed Care & Specialty Pharmacy® Previously published as JMCP, the Journal of Managed Care Pharmacy® A Peer-Reviewed Journal of the AMCP ■ www.jmcp.org ■ www.amcp.org AMCP Abstracts Program The AMCP NEXUS 2020 VIRTUAL will be held online the week of October 19, 2020. The AMCP abstracts program provides a forum through which authors can share their insights and outcomes of advanced managed care practice. For NEXUS 2020 VIRTUAL, abstract posters are scheduled to be presented Wednesday, October 21, from 1:00 pm EDT to 2:30 pm EDT. At that time, poster presenters will be available for live chats and will also share additional information about their research at https://plan.core-apps.com/ ■ Publisher amcp2020. Professional abstracts that have been reviewed are published in the Journal of Managed Susan A. Cantrell, RPh, CAE Care & Specialty Pharmacy’s (JMCP) Poster Abstracts supplement. Chief Executive Officer Academy of Managed Care Pharmacy Abstract Review Process ■ Editor-in-Chief Sixty-seven reviewers and 4 JMCP editorial reviewers were involved in the abstract review process Laura E. Happe, PharmD, MPH for AMCP NEXUS 2020 VIRTUAL. Each abstract (with author name and affiliation blinded) was 727.488.2700 reviewed and scored using a 1-5 scale with the following 5 criteria (15 rating scores per abstract), [email protected] which are used by JMCP to evaluate manuscripts for publication: ■ Assistant Editors • Relevance • Originality • Quality • Bias • Clarity Donald G.
    [Show full text]
  • Janus Kinases in Leukemia
    cancers Review Janus Kinases in Leukemia Juuli Raivola 1, Teemu Haikarainen 1, Bobin George Abraham 1 and Olli Silvennoinen 1,2,3,* 1 Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland; juuli.raivola@tuni.fi (J.R.); teemu.haikarainen@tuni.fi (T.H.); bobin.george.abraham@tuni.fi (B.G.A.) 2 Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, 00014 Helsinki, Finland 3 Fimlab Laboratories, Fimlab, 33520 Tampere, Finland * Correspondence: olli.silvennoinen@tuni.fi Simple Summary: Janus kinase/signal transducers and activators of transcription (JAK/STAT) path- way is a crucial cell signaling pathway that drives the development, differentiation, and function of immune cells and has an important role in blood cell formation. Mutations targeting this path- way can lead to overproduction of these cell types, giving rise to various hematological diseases. This review summarizes pathogenic JAK/STAT activation mechanisms and links known mutations and translocations to different leukemia. In addition, the review discusses the current therapeutic approaches used to inhibit constitutive, cytokine-independent activation of the pathway and the prospects of developing more specific potent JAK inhibitors. Abstract: Janus kinases (JAKs) transduce signals from dozens of extracellular cytokines and function as critical regulators of cell growth, differentiation, gene expression, and immune responses. Deregu- lation of JAK/STAT signaling is a central component in several human diseases including various types of leukemia and other malignancies and autoimmune diseases. Different types of leukemia harbor genomic aberrations in all four JAKs (JAK1, JAK2, JAK3, and TYK2), most of which are Citation: Raivola, J.; Haikarainen, T.; activating somatic mutations and less frequently translocations resulting in constitutively active JAK Abraham, B.G.; Silvennoinen, O.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]